In the field of immunotherapy, current strategies mainly include blocking immune checkpoints such as PD-1 and CTLA-4 by antibodies or small-molecule inhibitors, thereby “re-firing up” the anti-tumor immune response. The gene discussed is CTLA4; the disease is neoplasm.